Home Cart Sign in  
Chemical Structure| 10246-75-0 Chemical Structure| 10246-75-0

Structure of Hydroxyzine pamoate
CAS No.: 10246-75-0

Chemical Structure| 10246-75-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hydroxyzine pamoate is a histamine H1-receptor antagonist.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hydroxyzine pamoate

CAS No. :10246-75-0
Formula : C44H43ClN2O8
M.W : 763.27
SMILES Code : O=C(C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C4C=CC=CC4=C1)O.ClC5=CC=C(C(N6CCN(CCOCCO)CC6)C7=CC=CC=C7)C=C5
MDL No. :MFCD00058051

Safety of Hydroxyzine pamoate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P301+P312+P330

Related Pathways of Hydroxyzine pamoate

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00332163 Metastatic Colorectal Cancer ... More >> Skin Rash Skin Toxicities Colon Cancer Colorectal Cancer Less << Phase 2 Completed - -
NCT02797522 Hepatitis B Phase 1 Terminated(Company decision to... More >> discontinue trial) Less << - New Zealand ... More >> Auckland Clinical Studies Ltd Grafton, Auckland, New Zealand, 1011 Less <<
NCT02797522 - Terminated(Company decision to... More >> discontinue trial) Less << - -
NCT00332163 - Completed - -
NCT00460486 Encephalitis, Tick-Borne Phase 3 Completed - Poland ... More >> Centrum Badan Farmakologii Klinicznej monipol Krakow, Poland, 30-969 Niepubliczny ZOZ "Atarax" s.c. Olsztyn, Poland, 10-117 Niepubliczny ZOZ "VITA" Olsztyn, Poland, 10-295 "PANTAMED" Sp. z o.o. Olsztyn, Poland, 10-461 Less <<
NCT03678792 Opioid-Related Disorders ... More >> Opioid Withdrawal Less << Phase 3 Not yet recruiting November 2020 United States, Virginia ... More >> Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<
NCT02532322 Arnold-Chiari Malformation ... More >> Posterior Fossa Tumors Less << Phase 2 Withdrawn(not enough patients ... More >>meeting criteria) Less << October 2018 United States, District of Col... More >>umbia Children's National Health System Washington, District of Columbia, United States, 20010 Less <<
NCT02374567 Dementia Depr... More >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders Less << Phase 3 Terminated - Germany ... More >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany Less <<
NCT02186795 - Completed - United States, South Carolina ... More >> Medical University of South Carolina Charleston, South Carolina, United States, 29425 Less <<
NCT00597519 Cancer Leukem... More >>ia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma Less << Phase 2 Completed - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT03158376 Postoperative Pain ... More >> Chronic Pain Less << Phase 3 Recruiting July 2019 France ... More >> Department of Thoracic Surgery, Lille University Hospital Recruiting Lille, France, 59000 Contact: Sabrina Habchi, MD       habchi.s@hotmail.fr    Sub-Investigator: Sabrina HABCHI, MD          Principal Investigator: Jacques DESBORDES, MD          Sub-Investigator: Delphine DEBLAUWE, MD          Sub-Investigator: Catherine DUSSON, MD          Sub-Investigator: Jean-Michel WATTIER, MD          Sub-Investigator: Emmanuel ROBIN, MD          Sub-Investigator: Dobrin BOGDAN, MD          Sub-Investigator: Mouhamed MOUSSA, MD          Sub-Investigator: Caroline BRANDT, PA Less <<
NCT01683851 - Completed - United States, Texas ... More >> University of Texas Health Science Center-Dental School San Antonio, Texas, United States, 78229 University of Texas Health Science Center-Ricardo Salinas Dental Clinic San Antonio, Texas, United States, 78237 Less <<
NCT00260481 Drug Abuse Dr... More >>ug Dependence Less << Phase 2 Phase 3 Completed - United States, California ... More >> UCLA Integrated Substance Abuse Programs Los Angeles, California, United States, 90025 Less <<
NCT01557712 Major Depressive Disorder Phase 3 Completed - France ... More >> Centre hospitalier universitaire Grenoble, France, 38000 Less <<
NCT00597519 - Completed - -
NCT03703960 Patient With Bronchial Endosco... More >>py Less << Not Applicable Not yet recruiting December 2020 France ... More >> Chu Dijon Bourogne Dijon, France, 21000 Less <<
NCT02886351 Anxiety Not Applicable Unknown June 2018 -
NCT03453632 Epidermolysis Bullosa Simplex Phase 2 Phase 3 Not yet recruiting June 6, 2019 France ... More >> Hôpital Larrey - CHU Toulouse Not yet recruiting Toulouse, France, 31059 Contact: Juliette Mazereeuw-Hautier, Pr Less <<
NCT01360346 Critical Illness ... More >> Mechanical Ventilation Complication Less << Phase 3 Unknown December 2012 Italy ... More >> AO San Paolo - Polo Universitario Recruiting Milano, Italy, 20142 Contact: Giovanni Mistraletti, MD    +39.339.8245014    giovanni.mistraletti@unimi.it Less <<
NCT03091738 Cirrhosis Phase 4 Completed - United States, Virginia ... More >> Virginia Commonwealth University Richmond, Virginia, United States, 23298 Less <<
NCT01151696 Pain Phase 4 Completed - France ... More >> Universty Hospital Toulouse SAMU 31 Toulouse, France, 31059 Less <<
NCT01501591 Placebo Effect ... More >> Placebo Drug Interaction Less << Not Applicable Completed - Saudi Arabia ... More >> King Faisal Specialist Hospital & research Center Riyadh, Saudi Arabia, 11211 Less <<
NCT00162786 Healthy Phase 4 Terminated - Netherlands ... More >> Brain and Behaviour Institute Maastricht, Netherlands, 6229 ET Less <<
NCT01675986 Feeling Anxious Phase 2 Completed - France ... More >> CHU de POITIERS Poitiers, France, 86021 Less <<
NCT03728894 Behavior, Child Phase 3 Recruiting January 26, 2019 Syrian Arab Republic ... More >> Tishreen University Recruiting Latakia, Syrian Arab Republic Contact: Nabih Raslan, Dr    00963999140762    raslan.nabih@tishreen.edu.sy    Contact: Hashem Ibrahem, Dr    00963991524215    hashemibrahim99@gmail.com Less <<
NCT00570388 Alcohol Dependence Not Applicable Unknown September 2008 United States, Pennsylvania ... More >> Institute of Addiction Medicine Recruiting Philadelphia, Pennsylvania, United States, 19118 Contact: Jenny J Starosta, PhD    215-248-6025    2evolve@gmail.com    Contact: Joseph Volpicelli, MD, PhD    215-248-6025    volpj@aol.com    Principal Investigator: Jenny J Starosta, PhD          Principal Investigator: Joseph Volpicelli, MD, PhD Less <<
NCT01496911 Healthy Volunteers Phase 4 Completed - Netherlands ... More >> Royal Netherlands Navy Den Helder, Noord Holland, Netherlands, 1780CA Less <<
NCT01971853 Pain Not Applicable Terminated(Insufficient number... More >> of participants recruited) Less << - United States, Colorado ... More >> Children's Hospital Colorado Aurora, Colorado, United States, 80045 Less <<
NCT00661674 - Completed - -
NCT00661674 Substance-Related Disorders Not Applicable Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT03324828 Anxiety Phase 4 Not yet recruiting November 30, 2019 -
NCT01372670 Anxiety in Those Patients With... More >> Anorexia Nervosa Eating Disorder Not Otherwise Specified, BMI (<=18) Less << Phase 4 Withdrawn(Due to unforseen rec... More >>ruiting difficulties, the study was closed.) Less << - United States, Minnesota ... More >> Melrose Institute Minneapolis, Minnesota, United States, 55416 Less <<
NCT01250652 Chronic Urticaria Phase 4 Completed - Bulgaria ... More >> Medical University Sofia, Department of Allergology Sofia, Bulgaria, 1431 Less <<
NCT01055236 Pruritus Naus... More >>ea Vomiting Less << Phase 4 Completed - Thailand ... More >> Siriraj Hospital Bangkoknoi, Bangkok, Thailand, 10700 Less <<
NCT02814981 - Unknown October 2017 France ... More >> Alexandre Joachim Recruiting Caen, Basse Normandie, France, 14000 Contact: Joachim Alexandre, MD       alexandre-j@chu-caen.fr Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.31mL

0.26mL

0.13mL

6.55mL

1.31mL

0.66mL

13.10mL

2.62mL

1.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories